Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.
Yükleniyor...
Tarih
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[No abstract available]
Açıklama
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORK
Anahtar Kelimeler
Kaynak
Journal of Clinical Oncology
WoS Q Değeri
Scopus Q Değeri
Cilt
39
Sayı
15
